These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31174179)

  • 21. Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study.
    Luke JJ; Ghate SR; Kish J; Lee CH; McAllister L; Mehta S; Ndife B; Feinberg BA
    Future Oncol; 2019 Sep; 15(25):2933-2942. PubMed ID: 30799646
    [No Abstract]   [Full Text] [Related]  

  • 22. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
    N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Network Meta-Analysis of Short and Long-Term Efficacy of Targeted Therapy With Single or Double-Drug Regimens in the Treatment of Stage III/IV Malignant Melanoma Based on 16 Randomized Controlled Trials.
    Xie T; Huang CY; Kang X; Luo JS; Qin XM; Han F
    J Cell Biochem; 2018 Jan; 119(1):640-649. PubMed ID: 28628251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
    Daud A; Tsai K
    Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma.
    Sengul Samanci N; Çelik E; Bagcilar O; Erol BC; Bicki E; Oruc K; Bedir S; Degerli E; Derin S; Demirci NS; Demirelli FH
    Melanoma Res; 2020 Oct; 30(5):477-483. PubMed ID: 32898388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Target therapy versus dacarbazine in first-line treatment of advanced non-surgical and metastatic melanoma: budget impact analysis from the perspective of the Brazilian National Health System, 2018-2020.
    Corrêa FM; Guerra RL; Fernandes RRA; Souza MC; Zimmermann IR
    Epidemiol Serv Saude; 2019 Jun; 28(2):e2018325. PubMed ID: 31271637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma.
    Li SN; Wan X; Peng LB; Li YM; Li JH
    BMC Health Serv Res; 2023 Jan; 23(1):49. PubMed ID: 36653848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAF
    Chic N; Mezquita L; Aldea M; Chebib R; Caramella C; Planchard D; Besse B
    Clin Lung Cancer; 2021 Jan; 22(1):e54-e56. PubMed ID: 32896487
    [No Abstract]   [Full Text] [Related]  

  • 29. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dabrafenib plus trametinib in patients with BRAF
    Davies MA; Saiag P; Robert C; Grob JJ; Flaherty KT; Arance A; Chiarion-Sileni V; Thomas L; Lesimple T; Mortier L; Moschos SJ; Hogg D; Márquez-Rodas I; Del Vecchio M; Lebbé C; Meyer N; Zhang Y; Huang Y; Mookerjee B; Long GV
    Lancet Oncol; 2017 Jul; 18(7):863-873. PubMed ID: 28592387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of dabrafenib-trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF-V600 mutation: A systematic review and network meta-analysis.
    Garzón-Orjuela N; Prieto-Pinto L; Lasalvia P; Herrera D; Castrillón J; González-Bravo D; Castañeda-Cardona C; Rosselli D
    Dermatol Ther; 2020 Mar; 33(2):e13145. PubMed ID: 31664762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vemurafenib/dabrafenib and trametinib.
    Rissmann R; Hessel MH; Cohen AF
    Br J Clin Pharmacol; 2015 Oct; 80(4):765-7. PubMed ID: 25847075
    [No Abstract]   [Full Text] [Related]  

  • 33. The new paradigm of systemic therapies for metastatic melanoma.
    Volpe VO; Klufas DM; Hegde U; Grant-Kels JM
    J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uveitis and serous retinal detachment secondary to systemic dabrafenib and trametinib.
    Rueda-Rueda T; Sánchez-Vicente JL; Moruno-Rodríguez A; Molina-Socola FE; Martínez-Borrego AC; López-Herrero F
    Arch Soc Esp Oftalmol (Engl Ed); 2018 Sep; 93(9):458-462. PubMed ID: 29580759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF L597K mutation: an opportunity to treat.
    Lobo-Martins S; Pais HL; Soares-de-Almeida L; Costa L; Mansinho A; Teixeira de Sousa R
    Dermatol Online J; 2021 Jan; 27(1):. PubMed ID: 33560788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma].
    Sibaud V; Baric L; Cantagrel A; Di Palma M; Ederhy S; Paques M; Perlemuter G
    Bull Cancer; 2021 May; 108(5):528-543. PubMed ID: 33812673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dabrafenib therapy for advanced melanoma.
    Trinh VA; Davis JE; Anderson JE; Kim KB
    Ann Pharmacother; 2014 Apr; 48(4):519-29. PubMed ID: 24259661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma.
    Mistry HB; Orrell D; Eftimie R
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):325-332. PubMed ID: 29222604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients.
    Rousset M; Titier K; Bouchet S; Dutriaux C; Pham-Ledard A; Prey S; Canal-Raffin M; Molimard M
    Clin Chim Acta; 2017 Jul; 470():8-13. PubMed ID: 28412197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dabrafenib in combination with trametinib for the treatment of metastatic melanoma.
    Awad MM; Sullivan RJ
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):25-33. PubMed ID: 25473943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.